TY - JOUR T1 - Preliminary Experience on the Use of the Adnatest® System for Detection of Circulating Tumor Cells in Prostate Cancer Patients JF - Anticancer Research JO - Anticancer Res SP - 3507 LP - 3513 VL - 32 IS - 8 AU - TILMAN TODENHÖFER AU - JÖRG HENNENLOTTER AU - SUSAN FEYERABEND AU - STEFAN AUFDERKLAMM AU - JOHANNES MISCHINGER AU - URSULA KÜHS AU - VALENTINA GERBER AU - JASMIN FETISCH AU - DAVID SCHILLING AU - SIEGFRIED HAUCH AU - ARNULF STENZL AU - CHRISTIAN SCHWENTNER Y1 - 2012/08/01 UR - http://ar.iiarjournals.org/content/32/8/3507.abstract N2 - Background: The Adnatest® system combines immunomagnetic enrichment of epithelial cells with polymerase chain reaction for prostate cancer (PC)-specific transcripts for the detection circulating tumor cells (CTCs). We evaluated the Adnatest® in patients with castration-resistant PC receiving docetaxel chemotherapy. Patients and Methods: CTCs were assessed in 16 patients with castration-resistant PC before cycles one and three of chemotherapy. Furthermore, markers of stem cells and epithelial-mesenchymal transition were assessed. Treatment response was assessed by imaging and prostate-specific antigen measurements. Results: Before chemotherapy, 11 patients were Adnatest®-positive whereas five patients were Adnatest®-positive before cycle three. A positive Adnatest® correlated with radiological progression (p=0.02). Rates of disease progression in epidermal growth factor receptor (EGFR)-positive and -negative patients were 100% and 7.7% (p=0.03). Conclusion: In this preliminary study, the Adnatest® detected CTCs in a considerable proportion of patients with castration-resistant PC. First data on certain markers (EGFR and aldehyd dehydrogenase 1) encourage future studies investigating transcripts predicting treatment response. ER -